A subsequent government consultation in December described an “opt out” system, alongside increased transparency obligations on AI firms, as its “preferred option.” The consultation was “a pivotal opportunity to ensure...
“That was the case last year, but that’s still the case. So we only see this intensifying,” Brekelmans said. Brekelmans also expressed concern over Europe’s dependence on China for critical...
Civil society groups have accused the pharmaceutical industry of abusing the current system, and want to rein it in. The sector disputes this, however, and argues the perks must be...
Overturning the subsidies would eliminate a potential U.S. export market for solar modules and batteries that could be worth as much as $50 billion by 2030, according to another analysis...
It takes two to launch a new medicine Many of the decisions that impact when patients get access to a new medicine are outside a company’s control, in fact, two-thirds...
What we need is to work across Europe to build world-class, publicly controlled medical research capacity. Then, rather than handing over that research — or, indeed, the patient data underlying...
